Filing Flows › Protalix BioTherapeutics (PLX) › Q2 2026
Protalix BioTherapeutics (PLX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 12, 2026
Protalix BioTherapeutics (PLX) reported revenue of $19.9M for the second quarter 2026 (Q2 2026), +27% from a year earlier and -41% from the quarter before. Operating margin was 23.5%, net earnings $3.8M (19.0% of revenue).
Protalix BioTherapeutics, Q2 2026: revenue $19.9M (+27% year over year), operating margin 23.5%, net earnings $3.8M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.9M | -41% | +27% |
| Operating profit | $4.7M | -78% | +299% |
| Net earnings | $3.8M | -79% | 23× |
| Operating cash flow | −$10.4M | -147% | — |
What changed
Revenue was $19.9M in Q2 2026, up 27% year over year and down 41% from the previous quarter. GOODS was the largest line at 100% of revenue. GOODS added $4.4M year over year (up 28%), 104% of the total change. LICENSE AND R&D SERVICES declined 69%.
Operating profit was $4.7M, a 23.5% margin (up 16.0 points year over year). Of the extra revenue versus Q2 2025, 83% reached operating profit, above the 7% margin then. Total costs grew 5% against revenue growth of 27%. The fastest-growing cost line was Cost of revenue (+32%). Net earnings were $3.8M, up 2203% year over year. The effective tax rate was 22.3%.
Operating cash flow was −$10.4M. Non-cash charges added back $406K of depreciation and $398K of share-based compensation. Working capital and other items used $15.0M. Capital expenditures of $593K exceeded it, leaving free cash flow of −$11.0M.
Questions
What was Protalix BioTherapeutics' revenue in the second quarter 2026?
Protalix BioTherapeutics (PLX) reported revenue of $19.9M for the second quarter 2026 (Q2 2026), +27% from a year earlier and -41% from the quarter before.
Was Protalix BioTherapeutics profitable in the second quarter 2026?
Operating profit was $4.7M (23.5% of revenue) and net earnings $3.8M.